A rumor regarding Crispr Therapeutics (CRSP) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Shares of ...

As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

Alto Neuroscience, Inc.'s innovative approach to CNS disorder treatment and 2026 clinical milestones. Click here to find out why ANRO stock is a Buy.

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant ...

And the best news is that it likely still has plenty of upside potential. Given its current momentum, Eli Lilly could even ...

Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...